Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158240 | 0.82 | EPHX2 (0.37) | EPHX2FAAHMAPK1CNR2HPGD | |
| SCHEMBL6156352 | 0.82 | EPHX2 (0.37) | EPHX2FAAHMAPK1CNR2MEN1 | |
| SCHEMBL6156322 | 0.82 | EPHX2 (0.36) | EPHX2FAAHCNR2MEN1KMT2A | |
| SCHEMBL6156265 | 0.82 | MEN1 (0.34) | EPHX2FAAHMAPK1CNR2MEN1 | |
| SCHEMBL6155443 | 0.82 | MEN1 (0.34) | EPHX2FAAHMAPK1CNR2MEN1 | |
| SCHEMBL6154718 | 0.81 | EPHX2 (0.41) | EPHX2FAAHMAPK1HPGDKMT2A | |
| SCHEMBL6154919 | 0.80 | CYP2C19 (0.48) | EPHX2FAAHMAPK1CNR2MEN1 | |
| SCHEMBL6157063 | 0.80 | EPHX2 (0.38) | EPHX2FAAHMAPK1MEN1KMT2A | |
| SCHEMBL6155273 | 0.80 | EPHX2 (0.38) | EPHX2FAAHMAPK1CNR2MEN1 | |
| SCHEMBL6155027 | 0.79 | KDM4E (0.34) | MEN1HPGDCYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0584088-B1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RES (US) | 1999-10-27 | — | — | EP | claimed |
| US-5672608-A | INHIBIT RELEASE OF NEUROTRANSMITTERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-09-30 | — | — | US | claimed |
| US-5670519-A | NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-09-23 | — | — | US | claimed |
| US-5622968-A | ADMINISTERING TO BLOCK VOLTAGE SENSITIVE CALCIUM CHANNELS OF MAMMALIAN NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-1551830-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-07-13 | — | — | EP | disclosed |
| EP-0940139-B1 | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers | SCION PHARMACEUTICALS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6673557-B2 | ADMINISTERING SUBSTITUED GUANIDINE COMPOUNDS FOR THERAPY OF DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2004-01-06 | — | — | US | disclosed |
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6358696-B1 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF ONE OR MORE SUBSTITUTED GUANIDINES TO TREAT DECREASED BLOOD FLOW OR NUTRIENT SUPPLY TO RETINAL TISSUE OR OPTIC NERVE, OR RETINAL ISCHEMIA OR TRAUMA, OR OPTIC NERVE INJURY | WYETH | 2002-03-19 | — | — | US | disclosed |
| US-6242198-B1 | ADMINISTERING GUANIDINE COMPOUND | CAMBRIDGE NEUROSCIENCE, INC. | 2001-06-05 | — | — | US | disclosed |
| US-5637623-A | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-06-10 | — | — | US | disclosed |
| US-5622968-A | ADMINISTERING TO BLOCK VOLTAGE SENSITIVE CALCIUM CHANNELS OF MAMMALIAN NEURONAL CELLS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5614630-A | NEUROTRANSMITTER RELEASE MODULATOR | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1997-03-25 | — | — | US | disclosed |
| US-5403861-A | Treating or preventing nerve cell death | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0584088-A4 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS. | CAMBRIDGE NEUROSCIENCE RES (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0584088-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE RESEARCH, INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992014697-A1 | SUBSTITUTED GUANIDINES AND DERIVATIVES THEREOF AS MODULATORS OF NEUROTRANSMITTER RELEASE AND NOVEL METHODOLOGY FOR IDENTIFYING NEUROTRANSMITTER RELEASE BLOCKERS | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027801-A1 | Methods of treatment of eye trauma and disorders | RBP4, ALDH1A2, RBP1 | EPHX2 3426/4885FAAH 199/4885MAPK1 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.